Company: LCTX
Filing Date: 2025-03-10
Form Type: 10-K
Source: 0000950170-25-036309
Chunk: 157

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-03-10
Form: 10-K
Item: Item 1B
Chunk 157
---
 LONG-TERM LIABILITIES

    Deferred tax liability

    273

    273

    Deferred revenues, net of current portion

    14,433

    18,693

    Operating lease liabilities, net of current portion

    1,295

    1,979

    Finance lease liabilities, net of current portion

    67

    91

    Warrant liabilities

    6,161

    —

    TOTAL LIABILITIES

    36,206

    38,996

    Commitments and contingencies (Note 13)

    SHAREHOLDERS’ EQUITY

    Preferred shares, no par value, 2,000 shares authorized; none issued and    outstanding as of December 31, 2024 and 2023

    —

    —

    Common shares, no par value, 450,000 shares authorized as of    December 31, 2024 and 2023; 220,416 and 174,987 shares issued    and outstanding as of December 31, 2024 and 2023, respectively

    484,722

    451,343

    Accumulated other comprehensive loss

    (2,876
    )

    (3,068
    )

    Accumulated deficit

    (403,465
    )

    (384,856
    )

    Lineage's shareholders’ equity

    78,381

    63,419

    Noncontrolling deficit

    (1,369
    )

    (1,396
    )

    Total shareholders’ equity

    77,012

    62,023

    TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
     
    $
    113,218

    $
    101,019

See accompanying notes to the consolidated financial statements.

97

LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(IN THOUSANDS, EXCEPT PER SHARE DATA)

    Year Ended December 31,

    2024

    2023

    REVENUES:

    Collaboration revenues
     
    $
    8,149

    $
    7,588

    Royalties, license and other revenues

    1,350

    1,357

    Total revenues